Isoniazid metabolism and hepatotoxicity

The Glut athione S-Transferase Supergene Family: Regulation of GST and the Contribution of the lsoenzymes to Cancer Chemoprotection and Drug Resistance Part I

Hayes, J. D., & Pulford, D. J. (1995) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239509083491 · Cited by 3,464

The molecular biology of cytochrome P450s

Gonzalez, F. J. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00021-3 · Cited by 1,301

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949

Genetic Control of Isoniazid Metabolism in Man

Evans, D. A. P., Manley, K. A., & McKusick, V. A. (1960) · BMJ · doi:10.1136/bmj.2.5197.485 · Cited by 784

Mammalian Microsomal Cytochrome P450 Monooxygenase

Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F., & McRee, D. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80408-6 · Cited by 696

Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis

Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs, W. R., & Sacchettini, J. C. (1998) · Science · doi:10.1126/science.279.5347.98 · Cited by 682

Role of CYP2E1 in the Hepatotoxicity of Acetaminophen

Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., & Gonzalez, F. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.12063 · Cited by 656

Concise review of the glutathione S-transferases and their significance to toxicology

Eaton, D. (1999) · Toxicological Sciences · doi:10.1093/toxsci/49.2.156 · Cited by 627

Oxidative Stress, Toxicology, and Pharmacology of CYP2E1

Caro, A. A., & Cederbaum, A. I. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121704 · Cited by 512

Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis

MITCHELL, J. R., ZIMMERMAN, H. J., ISHAK, K. G., THORGEIRSSON, U. P., TIMBRELL, J. A., SNODGRASS, W. R., & NELSON, S. D. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-2-181 · Cited by 505

Human Arylamine N -Acetyltransferase Genes: Isolation, Chromosomal Localization, and Functional Expression

BLUM, M., GRANT, D. M., McBRIDE, W., HEIM, M., & MEYER, U. A. (1990) · DNA and Cell Biology · doi:10.1089/dna.1990.9.193 · Cited by 435

Polymorphism of the N -acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Lai, S.-L., Yang, S.-Y., Chang, F.-Y., & Lee, S.-D. (2002) · Hepatology · doi:10.1053/jhep.2002.32102 · Cited by 432

Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis

Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D. (2003) · Hepatology · doi:10.1053/jhep.2003.50144 · Cited by 426

Isoniazid-Associated Hepatitis in 114 Patients

Black, M., Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., & Epler, G. R. (1975) · Gastroenterology · doi:10.1016/s0016-5085(19)32568-5 · Cited by 370

Hepatotoxicity Associated With Isoniazid Preventive Therapy: A 7-Year Survey From a Public Health Tuberculosis Clinic

Nolan, C. M., Goldberg, S. V., & Buskin, S. E. (1999) · JAMA · doi:10.1001/jama.281.11.1014 · Cited by 368

The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance

Rawat, R., Whitty, A., & Tonge, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235848100 · Cited by 330

Glutathione S-transferase class Kappa: characterization by the cloning of rat mitochondrial GST and identification of a human homologue

PEMBLE, S. E., WARDLE, A. F., & TAYLOR, J. B. (1996) · Biochemical Journal · doi:10.1042/bj3190749 · Cited by 301

Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites

Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, D. J., & Keiser, H. R. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518170 · Cited by 300

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

Pharmacogenetics-based tuberculosis therapy research group, Azuma, J., Ohno, M., Kubota, R., Yokota, S., Nagai, T., Tsuyuguchi, K., Okuda, Y., Takashima, T., Kamimura, S., et al. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1429-9 · Cited by 278

Melatonin Metabolism: Neural Regulation of Pineal Serotonin: Acetyl Coenzyme A N -Acetyltransferase Activity

Klein, D. C., Weller, J. L., & Moore, R. Y. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.12.3107 · Cited by 263

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., et al. (2000) · PubMed · Cited by 251

Resistance to Carbon Tetrachloride-Induced Hepatotoxicity in Mice Which Lack CYP2E1 Expression

Wong, F. W.-Y., Chan, W.-Y., & Lee, S. S.-T. (1998) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8547 · Cited by 251

Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.

Grant, D. M., Blum, M., Beer, M., & Meyer, U. A. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10988-7 · Cited by 246

Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat

Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Snodgrass, W. R., & Corcoran, G. B. (1976) · Science · doi:10.1126/science.7838 · Cited by 226

Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury

Huang, Y.-S., Su, W.-J., Huang, Y.-H., Chen, C.-Y., Chang, F.-Y., Lin, H.-C., & Lee, S.-D. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.009 · Cited by 212

Clinical Pharmacokinetics of Isoniazid

Weber, W. W., & Hein, D. W. (1979) · Clinical Pharmacokinetics · doi:10.2165/00003088-197904060-00001 · Cited by 207

Cyclic ADP-ribose and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) as Messengers for Calcium Mobilization

Lee, H. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.349464 · Cited by 197

Glutathione S‐transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug‐induced liver injury†

Lucena, M. I., Andrade, R. J., Martínez, C., Ulzurrun, E., García‐Martín, E., Borraz, Y., Fernández, M. C., Romero‐Gomez, M., Castiella, A., Planas, R., et al. (2008) · Hepatology · doi:10.1002/hep.22370 · Cited by 195

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

Vuilleumier, N., Rossier, M. F., Chiappe, A., Degoumois, F., Dayer, P., Mermillod, B., Nicod, L., Desmeules, J., & Hochstrasser, D. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0111-5 · Cited by 191

Current Concepts in the Management of Tuberculosis

Sia, I. G., & Wieland, M. L. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0820 · Cited by 190

A Fresh Look at the Mechanism of Isoniazid-Induced Hepatotoxicity

Metushi, I. G., Cai, P., Zhu, X., Nakagawa, T., & Uetrecht, J. P. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.355 · Cited by 190

Increased risk of antituberculosis drug‐induced hepatotoxicity in individuals with glutathione S‐transferase M1 ‘null’ mutation

Roy, B., Chowdhury, A., Kundu, S., Santra, A., Dey, B., Chakraborty, M., & Majumder, P. P. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02585.x · Cited by 187

Structure of arylamine N-acetyltransferase reveals a catalytic triad

Noble, M. E. M., Sinclair, J. C., Sandy, J., Delgoda, R., & Sim, E. (2000) · Nature Structural Biology · doi:10.1038/76783 · Cited by 187

Arylamine N‐acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery

Sim, E., Abuhammad, A., & Ryan, A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12598 · Cited by 185

Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A

Desta, Z., Soukhova, N. V., & Flockhart, D. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.382-392.2001 · Cited by 180

Isoniazid Hepatitis

MADDREY, W. C., & BOITNOTT, J. K. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-1-1 · Cited by 175

Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis

Cho, H.-J., Koh, W.-J., Ryu, Y.-J., Ki, C.-S., Nam, M.-H., Kim, J.-W., & Lee, S.-Y. (2007) · Tuberculosis · doi:10.1016/j.tube.2007.05.012 · Cited by 173

Human carboxylesterases and their role in xenobiotic and endobiotic metabolism

Ross, M. K., & Crow, J. A. (2007) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20178 · Cited by 169

Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.

Timbrell, J. A., Mitchell, J. R., Snodgrass, W. R., & Nelson, S. D. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32069-0 · Cited by 161

Localization of N-Acetyltransferases NAT1 and NAT2 in Human Tissues

Windmill, K. (2000) · Toxicological Sciences · doi:10.1093/toxsci/54.1.19 · Cited by 159

Isoniazid is a mechanism-based inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

Wen, X., Wang, J., Neuvonen, P. J., & Backman, J. T. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0396-3 · Cited by 157

Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles

Bhandari, R., & Kaur, I. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.11.042 · Cited by 156

Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients

Teixeira, R. L. D. F., Morato, R. G., Cabello, P. H., Muniz, L. M. K., Moreira, A. D. S. R., Kritski, A. L., Mello, F. C. D. Q., Suffys, P. N., de Miranda, A. B., & Santos, A. R. (2011) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762011000600011 · Cited by 148

Isoniazid: Metabolic Aspects and Toxicological Correlates

Preziosi, P. (2007) · Current Drug Metabolism · doi:10.2174/138920007782798216 · Cited by 146

Genetic Polymorphism in N-Acetyltransferase (NAT): Population Distribution of NAT1 and NAT2 Activity

Walker, K., Ginsberg, G., Hattis, D., Johns, D. O., Guyton, K. Z., & Sonawane, B. (2009) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400903158383 · Cited by 140

Mechanisms of isoniazid‐induced idiosyncratic liver injury: Emerging role of mitochondrial stress

Boelsterli, U. A., & Lee, K. K. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12516 · Cited by 137

Detection of anti-isoniazid and anti–cytochrome P450 antibodies in patients with isoniazid-induced liver failure

Metushi, I. G., Sanders, C. M., Lee, W. M., & Uetrecht, J. (2013) · Hepatology · doi:10.1002/hep.26564 · Cited by 134

Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.

Sarma, G. R., Immanuel, C., Kailasam, S., Narayana, A. S. L., & Venkatesan, P. (1986) · PubMed · doi:10.1164/arrd.1986.133.6.1072 · Cited by 116

Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis

Cai, Y., Yi, J., Zhou, C., & Shen, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047769 · Cited by 116

Arylamine N-acetyltransferases – of mice, men and microorganisms

Upton, A. M., Johnson, N., Sandy, J., & Sim, E. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01639-4 · Cited by 113

Direct Oxidation and Covalent Binding of Isoniazid to Rodent Liver and Human Hepatic Microsomes: Humans Are More Like Mice than Rats

Metushi, I. G., Nakagawa, T., & Uetrecht, J. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300341r · Cited by 108

Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits

Sarich, T. C., Youssefi, M., Zhou, T., Adams, S. P., Wall, R. A., & Wright, J. M. (1996) · Archives of Toxicology · doi:10.1007/s002040050347 · Cited by 106

Plasma Hydrazine Concentrations in Man after Isoniazid and Hydralazine Administration

Blair, I. A., Tinoco, R. M., Brodie, M. J., Clare, R. A., Dollery, C. T., Timbrell, J. A., & Beever, I. A. (1985) · Human Toxicology · doi:10.1177/096032718500400210 · Cited by 98

Inhibition of Isoniazid-Induced Hepatotoxicity in Rabbits by Pretreatment with an Amidase Inhibitor

Sarich, T. C., Adams, S. P., Petricca, G., & Wright, J. M. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38190-x · Cited by 95

Conjugation-deconjugation reactions in drug metabolism and toxicity

(1995) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(99)80002-0 · Cited by 95

Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances

Hall, R. G., Leff, R. D., & Gumbo, T. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.12.1468 · Cited by 89

Induction of Hepatic Microsomal Enzymes after Brief Administration of Rifampicin in Man

Miguet, J., Mavier, P., Soussy, C., & Dhumeaux, D. (1977) · Gastroenterology · doi:10.1016/s0016-5085(77)80212-6 · Cited by 79

Eubacterial arylamine N-acetyltransferases – identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues

Payton, M. A., Mushtaq, A., Yu, T., Wu, L. J., Sinclair, J., & Sim, E. (2001) · Microbiology · doi:10.1099/00221287-147-5-1137 · Cited by 78

Mechanism-based Inhibition of CYP450: An Indicator of Drug-induced Hepatotoxicity

Feng, S., & He, X. (2013) · Current Drug Metabolism · doi:10.2174/138920021131400114 · Cited by 74

Genetic Variations of NAT2 and CYP2E1 and Isoniazid Hepatotoxicity in a Diverse Population

Yamada, S., Tang, M., Richardson, K., Halaschek-Wiener, J., Chan, M. S., Cook, V. J., FitzGerald, J. M., Elwood, R. K., Brooks-Wilson, A. R., & Marra, F. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.66 · Cited by 74

Association of N ‐acetyltransferase 2 and cytochrome P 450 2 E 1 gene polymorphisms with antituberculosis drug‐induced hepatotoxicity in W estern I ndia

Gupta, V. H., Amarapurkar, D. N., Singh, M. M., Sasi, P., Joshi, J. M., Baijal, R., Ramegowda, P. H., Amarapurkar, A. D., Joshi, K., & Wangikar, P. P. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12194 · Cited by 71

Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes

Lee, K. K., Fujimoto, K., Zhang, C., Schwall, C. T., Alder, N. N., Pinkert, C. A., Krueger, W. H., Rasmussen, T. P., & Boelsterli, U. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.038 · Cited by 71

Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs

Chamorro, J. G., Castagnino, J. P., Musella, R. M., Nogueras, M., Aranda, F. M., Frías, A., Visca, M., Aidar, O., Wingeyer, S. D. P., & Larrañaga, G. F. D. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12069 · Cited by 67

Elevated Serum Aminotransferase Induced by Isoniazid in Relation to Isoniazid Acetylator Phenotype

Yamamoto, T., Suou, T., & Hirayama, C. (1986) · Hepatology · doi:10.1002/hep.1840060223 · Cited by 66

Effects of Gender, AIDS, and Acetylator Status on Intrapulmonary Concentrations of Isoniazid

Conte, J. E., Golden, J. A., McQuitty, M., Kipps, J., Duncan, S., McKenna, E., & Zurlinden, E. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2358-2364.2002 · Cited by 65

Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury

Huang, Y. (2014) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.01.010 · Cited by 64

The Incidence of Liver Injury in Uyghur Patients Treated for TB in Xinjiang Uyghur Autonomous Region, China, and Its Association with Hepatic Enzyme Polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1

Xiang, Y., Ma, L., Wu, W., Liu, W., Li, Y., Zhu, X., Wang, Q., Ma, J., Cao, M., Wang, Q., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085905 · Cited by 64

Rifampicin exacerbates isoniazid‐induced toxicity in human but not in rat hepatocytes in tissue‐like cultures

Shen, C., Meng, Q., Zhang, G., & Hu, W. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707611 · Cited by 61

Enzyme kinetic properties of human recombinant arylamine n-acetyltransferase 2 allotypic variants expressed in Escherichia coli

Hickman, D., Palamanda, J. R., Unadkat, J. D., & Sim, E. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00182-y · Cited by 57

N-acetyltransferase 2 Slow Acetylator Genotype Associated with Adverse Effects of Sulfasalazine in the Treatment of Inflammatory Bowel Disease

Chen, M., Xia, B., Chen, B., Guo, Q., Jin, L., Ye, M., & Hu, Z. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/976804 · Cited by 55

Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity

Yamada, S., Richardson, K., Tang, M., Halaschek-Wiener, J., Cook, V. J., FitzGerald, J. M., Elwood, K., Marra, F., & Brooks-Wilson, A. R. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.5 · Cited by 53

A Systems Biology Approach Utilizing a Mouse Diversity Panel Identifies Genetic Differences Influencing Isoniazid-Induced Microvesicular Steatosis

Church, R. J., Wu, H., Mosedale, M., Sumner, S., Pathmasiri, W., Kurtz, C. L., Pletcher, M. T., Eaddy, J. S., Pandher, K., Singer, M. M., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu094 · Cited by 52

Hepatic Gene Expression and Lipid Homeostasis in C57Bl/6 Mice Exposed to Hydrazine or Acetylhydrazine

Richards, V. E. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh232 · Cited by 51

A Novel Metabolite of Antituberculosis Therapy Demonstrates Host Activation of Isoniazid and Formation of the Isoniazid-NAD+Adduct

Mahapatra, S., Woolhiser, L. K., Lenaerts, A. J. M., Johnson, J. L., Eisenach, K. D., Joloba, M. L., Boom, W. H., & Belisle, J. T. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05486-11 · Cited by 47

GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs

Chatterjee, S., Lyle, N., Mandal, A., & Kundu, S. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01101.x · Cited by 46

Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity

Hayashi, P. H., Fontana, R. J., Chalasani, N. P., Stolz, A. A., Talwalkar, J. A., Navarro, V. J., Lee, W. M., Davern, T. J., Kleiner, D. E., Gu, J., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.02.024 · Cited by 45

Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits

Šimůnek, T., Klimtová, I., Kaplanová, J., Štěrba, M., Mazurová, Y., Adamcová, M., Hrdina, R., Geršl, V., & Poňka, P. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.08.005 · Cited by 44

Auto-oxidation of Isoniazid Leads to Isonicotinic-Lysine Adducts on Human Serum Albumin

Meng, X., Maggs, J. L., Usui, T., Whitaker, P., French, N. S., Naisbitt, D. J., & Park, B. K. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500285k · Cited by 40

The roles ofGSTM1andGSTT1null genotypes and other predictors in anti-tuberculosis drug-induced liver injury

Monteiro, T. P., El-Jaick, K. B., Jeovanio-Silva, A. L., do Brasil, P. E. A. A., Costa, M. J. M., Rolla, V. C., & de Castro, L. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01368.x · Cited by 32

Isoniazid Inhibits the Heme-Based Reactivity of Mycobacterium tuberculosis Truncated Hemoglobin N

Ascenzi, P., Coletta, A., Cao, Y., Trezza, V., Leboffe, L., Fanali, G., Fasano, M., Pesce, A., Ciaccio, C., Marini, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069762 · Cited by 32

Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients

Gent, W. L. G., Seifart, H. I., Parkin, D. P., Donald, P. R., & Lamprecht, J. H. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf01740658 · Cited by 31

Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD+ adduct formation: A comparison of the reactivity of isoniazid with its known human metabolites

Khan, S. R., Morgan, A. G. M., Michail, K., Srivastava, N., Whittal, R. M., Aljuhani, N., & Siraki, A. G. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.02.003 · Cited by 31

Molecular Biology of the Enzymes that Degrade Endocannabinoids

Puffenbarger, R. A. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/156800705774933050 · Cited by 29

Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients

Requena‐Méndez, A., Davies, G., Waterhouse, D., Ardrey, A., Jave, O., López-Romero, S. L., Ward, S. A., & Moore, D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03258-14 · Cited by 28

The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats

Mach, J., Huizer‐Pajkos, A., Mitchell, S. J., McKenzie, C. A., Phillips, L., Kane, A. E., Jones, B., de Cabo, R., Cogger, V. C., Couteur, D. G. L., et al. (2015) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12157 · Cited by 27

Oxidative stress potentiated by diallylsulfide, a selective CYP2E1 inhibitor, in isoniazid toxic effect on rat primary hepatocytes

Zhai, Q., Lu, S., LIN, Y., Yang, Q., & Yu, B. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.10.007 · Cited by 26

Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid.

Peretti, E., Karlaganis, G., & Lauterburg, B. H. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11049-5 · Cited by 23

Letter to the Editor

Leiro‐Fernández, V., Valverde, D., Vázquez-Gallardo, R., Constenla, L., & Fernández‐Villar, A. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.109 · Cited by 11

Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: A review

Zhuang, X., Li, L., Liu, T., Zhang, R., Yang, P., Wang, X., & Dai, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1037814 · Cited by 88

Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens

Nicoletti, P., Devarbhavi, H., Goel, A., Venkatesan, R., Eapen, C. E., Grove, J. I., Zafer, S., Bjornsson, E., Lucena, M. I., Andrade, R. J., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2100 · Cited by 61